AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy
Rodney H Falk1, Kevin M Alexander1, Ronglih Liao1
1Brigham and Women's Hospital Cardiac Amyloidosis Program, Harvard Medical School and Department of Medicine, Section of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract:
The amyloidoses are a group of protein-folding disorders in which ≥1 organ is infiltrated by proteinaceous deposits known as amyloid. The deposits are derived from 1 of several amyloidogenic precursor proteins, and the prognosis of the disease is determined both by the organ(s) involved and the type of amyloid. Amyloid involvement of the heart (cardiac amyloidosis) carries the worst prognosis of any involved organ, and light-chain (AL) amyloidosis is the most serious form of the disease. The last decade has seen considerable progress in understanding the amyloidoses. In this review, current and novel approaches to the diagnosis and treatment of cardiac amyloidosis are discussed, with particular reference to AL amyloidosis in the heart.
Related Concept Videos
Amyloid Fibrils
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...


